Canafenib combined with cetuximab in the treatment of BRAF V600E-mutant mCRC

In December 2024, the U.S. Food and Drug Administration (FDA) approved accelerated approval of canafenib (Encorafenib) in combination with cetuximab and mFOLFOX6 (fluorouracil, aldehyde hydrofolic acid, and oxaliplatin) for the treatment of patients with BRAF Patients with V600E-mutated metastatic colorectal cancer (mCRC), which is detected by an FDA-approved test.

Historically, Patients with BRAF V600E-mutated CRC have had limited targeted therapy options, with canafenib plus cetuximab only available in the second-line setting after disease progression on standard chemotherapy. However, BRAFV600E-mutated CRCs have aggressive tumor biology and poor overall survival (OS) outcomes, she said. She pointed out that even with intensive chemotherapy regimens such as FOLFIRINOX (fluorouracil, oxaliplatin, irinotecan, and aldehyde folic acid) plus bevacizumab, the median OS in this population is still shorter than 18 months.

The FDA approved canafenib in combination with cetuximab and mFOLFOX6 as a first-line treatment for this population, marking a major advancement in the treatment paradigm. This development highlights the urgent need for rapid genomic analysis at the time of diagnosis to identify BRAF mutations as early as possible and rapidly initiate the most effective treatments. Given the poor prognosis caused by BRAF V600E mutations, optimizing first-line treatment is very important to improve patient prognosis.

Patients with BRAF V600E mutated mCRC who receive standard chemotherapy, includingFOLFIRINOX, have a limited response, with a median OS of only about 14 to 17 months. Additionally, in the second-line setting, the median progression-free survival (PFS) with canafenib plus cetuximab was approximately 4 months, and the second-line median OS was approximately 9 months. The introduction of this first-line targeted regimen is promising, as it demonstrated an overall response rate of 61% (95% CI, 52%-70%) in the pivotal Phase 3 BREAKWATER trial (NCT04607421), compared with 40% (95% CI, 31%-49%) with chemotherapy alone.

Therefore, the FDA approved canafenib plus cetuximab (cetuximab) and chemotherapy in patients with BRAF V600E mutated mCRC. As OS and PFS data continue to mature, this approach may redefine the standard of care for this population, reinforcing the need for precision medicine approaches in the frontline setting to optimize outcomes.

Reference materials:https://www.onclive.com/view/dr-chiorean-on-encorafenib-plus-cetuximab-for-braf-v600e-mutated-mcrc?utm_source=www.onclive.com&utm_medium=recentVideos